Specifications and structural formula of venetoclax/venetoclax

Venetoclax/Venetoclax is a selective BCL-2 inhibitor widely used to treat certain types of blood cancers, such as chronic lymphocytic leukemia (CLL) and acute myeloid leukemia (AML). Its chemical structure is complex, its empirical formula is C45H50ClN7O7S, and its molecular weight is 868.44. The molecular structure of venetoclax contains multiple functional groups. The configuration and combination of these functional groups enable it to effectively bind to BCL-2 protein, thereby inducing apoptosis of cancer cells.

Chemically, the structure of veneclat can be described as4-(4-{[2-(4-chlorophenyl)-4,4-dicyclohex-1-en-1-yl]piperazine- 1-yl}-N-({3-amino-4-[(tetrahydro2H-pyran-4-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide). Its complex chemical structure makes the drug highly selective and able to effectively inhibit the function of BCL-2 protein, thereby promoting the death of cancer cells.

Veneclat is usually provided in the form of oral tablets, which are light yellow or beige in color and available in three strengths: 10mg, 50mg and 100mg. This drug is administered orally, and patients can take it according to the guidance of their doctor. The metabolism of venetoclax in the body is primarily carried out by the liver, specifically by the CYP3A4 enzyme. During the course of taking it, patients need to regularly monitor blood indicators to evaluate the efficacy and potential side effects of the drug.

The clinical application of venetoclax demonstrates the importance of targeted therapy in tumor drug development and also highlightsBCL-2’s key role as an anti-apoptotic protein in tumor biology. Through the rational use of such drugs, patients' survival rate and quality of life can be significantly improved. However, due to the possible side effects, patients should follow their doctor's advice when using venetoclax and undergo regular medical examinations to ensure the safety of the medication.

Reference materials:https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b118a40d-6b56-cee3-10f6-ded821a97018##